Xingkerong Pharmaceutical (06833) announced that Li Jianwei has resigned as the company's joint company secretary and the Hong Kong Stock Exchange Limited...
According to the Zhitong Finance App, Xing Kerong Pharmaceutical (06833) announced that Li Jianwei has resigned as the company's joint company secretary and the company's authorized representative under section 3.05 of the Hong Kong Stock Exchange Limited securities listing rules, effective from March 26, 2024.
After Mr. Li resigns, another joint company secretary, Peng Yunlu, will continue to serve as the company's sole company secretary. Ms Pang has been recognized as a member of the Hong Kong Corporate Governance Association and is therefore eligible as a company secretary under sections 3.28 and 8.17 of the Listing Rules. Ms. Pang has also been appointed as an authorized representative to replace Mr. Lee with effect from March 26, 2024.
According to section 16.2 of the company's memorandum and articles of association, Huang Zhijian was appointed as the company's executive director, effective from March 26, 2024 until the next annual general meeting of shareholders of the company after his appointment. At that time, he will be eligible for re-election at the meeting.